Overview

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Status:
Completed

Trial end date:
2017-09-14

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment, and increase the time this response lasts, for patients with previously untreated CLL. The safety of this combination will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Genentech, Inc.
OSI Pharmaceuticals

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenograstim
Mitoxantrone
Rituximab
Vidarabine